Semaglutide, a GLP-1 receptor agonist approved by the FDA for chronic weight management, does reduce abdominal fatbut not through spot reduction
Another emerging pillar of neuroprotection involves NIBS, particularly tDCS and repetitive transcranial magnetic stimulation (rTMS)
However, like any medication, there may be potential side effects such as nausea, constipation, gastrointestinal distress, or diarrhea
Additionally, GHK-Cus effects on blood vessel growth may help ensure hair follicles receive adequate blood supply and nutrients
If you have a personal or family history of certain conditions, such as pancreatitis or medullary thyroid carcinoma, or are pregnant or breastfeeding, this treatment approach is not recommended for you
Conditions like obesity with diabetes, sleep apnea, or hypertension call for evidencebased medical care rather than a supplement experiment